Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593034 | 0.83 | HTR2A (0.31) | HTR2A | |
| SCHEMBL4295538 | 0.67 | HTR2A (0.38) | HTR2A | |
| SCHEMBL13782351 | 0.67 | HTR2A (0.38) | HTR2A | |
| SCHEMBL16118077 | 0.67 | — | — | |
| SCHEMBL13782587 | 0.67 | HTR2A (0.38) | HTR2A | |
| SCHEMBL10578702 | 0.67 | HTR2A (0.38) | HTR2A | |
| SCHEMBL8285073 | 0.67 | BRD4 (0.38) | HTR2A | |
| SCHEMBL15987500 | 0.67 | HTR2A (0.38) | HTR2A | |
| SCHEMBL2640847 | 0.67 | HTR2A (0.42) | HTR2A | |
| SCHEMBL28164517 | 0.67 | HTR2A (0.38) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11289660-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-03-29 | — | — | US | claimed |
| EP-3530658-A2 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Display Co., Ltd. (KR) | 2019-08-28 | — | — | EP | claimed |
| US-20190237679-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-08-01 | — | — | US | claimed |
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | US | claimed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | claimed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | claimed |
| WO-2009109610-A1 | USE OF NAD INFORMATION INHIBITORS FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY | TOPOTARGET SWITZERLAND S.A. (CH) | 2009-09-11 | — | — | WO | claimed |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-08-27 | — | — | US | claimed |
| EP-2073808-A2 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | Topotarget Switzerland SA (CH) | 2009-07-01 | — | — | EP | claimed |
| JP-2000512652-A | — | — | 2000-09-26 | — | — | JP | claimed |
| EP-0934309-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-08-11 | — | — | EP | claimed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| EP-0923570-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-06-23 | — | — | EP | claimed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | claimed |
| WO-1997048397-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048696-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048695-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11289660-B2 | Heterocyclic compound and organic light-emitting device including the same | CRY1, CRY2, SUN2 | HTR2A 1636/4885 |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | HTR2A 1697/4885 |
| US-20190237679-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, SUN2 | HTR2A 1636/4885 |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | HTR2A 1697/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | HTR2A 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.